John Radford

30.0k citations
385 papers · 16.8k · 5 hit papers · h-index 68

Impact in

Papers in

John Radford

373 papers receiving 16.1k citations

John Radford's Hit Papers

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 284 citations
2840+9+18Years since publication250500750

Peers

John Radford
Comparison fields: 5 of 170
  • Pathology and Forensic Medicine 8.4k
  • Oncology 6.8k
  • Genetics 2.7k
  • Neurology 2.1k
  • Reproductive Medicine 892
Replace Sandra J. Horning with:
Sandra J. Horning United States
Andreas Engert Germany
F. Anthony Greco United States
John P. Leonard United States
Gianni Bonadonna Italy
Pinuccia Valagussa Italy
Nancy L. Bartlett United States
Matthew J. Maurer United States
Mark Krailo United States
D. Crowther United Kingdom
John Radford relative to Sandra J. Horning United States Sandra J. Horning's profile →
Citations per field
00.5×2.7×
Sandra J. Horning · 1×
Citations per year

Countries citing papers authored by John Radford

Since Specialization
Citations

This map shows the geographic impact of John Radford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Radford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Radford more than expected).

Fields of papers citing papers by John Radford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Radford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Radford. The network helps show where John Radford may publish in the future.

Co-authors

The 25 scholars most cited alongside John Radford, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Radford Line = papers co-authored together John Radford links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 385 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Hit paper breakdown →
1998753
2
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Hit paper breakdown →
2017721
3
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Hit paper breakdown →
2015439
4 2000392
5
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
Hit paper breakdown →
2013379
6 2005355
7 1992348
8 2007347
9 2008343
10 2003340
11 2001317
12 2000301
13 2001293
14
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Hit paper breakdown →
2021284
15 1992281
16 2010254
17 2019233
18 2008213
19 1999210
20 2007200

About John Radford

John Radford is a scholar working on Pathology and Forensic Medicine, Oncology, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 385 papers that have together received 16.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (229 papers), Chronic Lymphocytic Leukemia Research (77 papers), Lung Cancer Treatments and Mutations (60 papers), Viral-associated cancers and disorders (42 papers), CAR-T cell therapy research (37 papers), CNS Lymphoma Diagnosis and Treatment (35 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Pathology and Forensic Medicine (8.4k citations), Oncology (6.8k citations), Genetics (2.7k citations), Neurology (2.1k citations) and Reproductive Medicine (892 citations). John Radford has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Peter Johnson, D. Crowther, A. Z. S. Rohatiner, Ruth Pettengell, David Cunningham, David C. Linch, Barry W. Hancock, Pier Luigi Zinzani, Jean‐Yves Blay and Martin Harris. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact